Evidence mapPaperPMID 33139554Full record

ArticleProceedings of the National Academy of Sciences of the United States of America2020

Evidence for aggregation-independent, PrP

Alejandro R Foley, Graham P Roseman, Ka Chan, Amanda Smart, Thomas S Finn, Kevin Yang, R Scott Lokey, Glenn L Millhauser, Jevgenij A Raskatov

Open access · bronzeAbstract read
In one paragraph

Article in Proceedings of the National Academy of Sciences of the United States of America, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed
2.9field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 36 citations in OpenAlex.

  1. Trial
  2. Review
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Review
  11. Review
  12. Article
  13. Article
  14. Review
  15. Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Alejandro R FoleyDepartment of Chemistry and Biochemistry, University of California, Santa Cruz, CA 95064.ORCID 0000-0002-8644-0546
Graham P RosemanDepartment of Chemistry and Biochemistry, University of California, Santa Cruz, CA 95064.ORCID 0000-0002-5342-1373
Ka ChanDepartment of Chemistry and Biochemistry, University of California, Santa Cruz, CA 95064.
Amanda SmartDepartment of Chemistry and Biochemistry, University of California, Santa Cruz, CA 95064.
Thomas S FinnDepartment of Chemistry and Biochemistry, University of California, Santa Cruz, CA 95064.ORCID 0000-0002-4522-5321
Kevin YangDepartment of Chemistry and Biochemistry, University of California, Santa Cruz, CA 95064.
R Scott LokeyDepartment of Chemistry and Biochemistry, University of California, Santa Cruz, CA 95064.ORCID 0000-0001-9891-1248
Glenn L MillhauserDepartment of Chemistry and Biochemistry, University of California, Santa Cruz, CA 95064 glennm@ucsc.edu jraskato@ucsc.edu.ORCID 0000-0003-2442-7220
Jevgenij A RaskatovDepartment of Chemistry and Biochemistry, University of California, Santa Cruz, CA 95064 glennm@ucsc.edu jraskato@ucsc.edu.
University of California, Santa Cruz · US

Funding

UNIVERSITY OF CALIFORNIA, SANTA CRUZ IMSD PROGRAMR25GM058903 · UNIVERSITY OF CALIFORNIA SANTA CRUZ · 1999 to 2005
$2.9M
Cyclic peptide permeabilityR01GM131135 · NIGMS · UNIVERSITY OF CALIFORNIA SANTA CRUZ · PI Robert SCOTT LOKEY · 2021 to 2022
$616k
UC Santa Cruz PREPR25GM104552 · UNIVERSITY OF CALIFORNIA SANTA CRUZ · 2025 to 2025
$432k
Discovering How Cu(II)/Zn(II) Uptake by the Prion Protein Controls Structure, Function and NeurotoxicityR35GM131781 · UNIVERSITY OF CALIFORNIA SANTA CRUZ · 2025 to 2025
$414k
NIA NIH HHS R21 AG058074NIGMS NIH HHS R01 GM131135NIGMS NIH HHS R25 GM058903NIGMS NIH HHS R25 GM104552NIGMS NIH HHS R35 GM131781NIH HHS S10 OD018455NIH HHS S10 OD024980
6 · The paper itself

Abstract

Evidence linking amyloid beta (Aβ) cellular uptake and toxicity has burgeoned, and mechanisms underlying this association are subjects of active research. Two major, interconnected questions are whether Aβ uptake is aggregation-dependent and whether it is sequence-specific. We recently reported that the neuronal uptake of Aβ depends significantly on peptide chirality, suggesting that the process is predominantly receptor-mediated. Over the past decade, the cellular prion protein (PrP

Indexed as

Amyloid beta-PeptidesHEK293 CellsHumansPeptide FragmentsPrPC Proteinsamyloid beta-peptide (1-30)Amyloid beta-PeptidesPeptide FragmentsPrPC ProteinsAlzheimer’s diseaseamyloid βmirror-image peptidesprion protein (PrP)receptor-mediated internalization

Identifiers

PMID33139554
PMCPMC7682355
OpenAlexW3095445698

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.